End-of-day quote
Korea S.E.
06:00:00 2024-05-09 pm EDT
5-day change
1st Jan Change
9,340
KRW
-5.56%
-11.89%
+113.00%
HLB Therapeutics Co.,Ltd. announced that it has received KRW 13.0088 billion in funding from HLB Co., Ltd.
On January 12, 2023, HLB Therapeutics Co.,Ltd. closed the transaction. The scheduled expected listing date of new shares is February 2, 2023.
HLB Therapeutics Co.,Ltd. announced that it has received KRW 29.99999658 billion in funding from HLB Co., Ltd.
Mar. 31
CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 18
CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 14
CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
CI
HLB Life Science Co., Ltd. announced that it has received KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.
23-07-06
CI
HLB Life Science Co., Ltd. announced that it expects to receive KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.
23-06-28
CI
Panagene Inc. announced that it expects to receive KRW 56.599994061 billion in funding from a group of investors
23-06-20
CI
Panagene Inc. announced that it expects to receive KRW 46.068324061 billion in funding from HLB Co., Ltd., HLB Investment Co., Ltd., HLB bioStep Co.,Ltd., HLB innoVation Co.,Ltd., HLB Therapeutics Co.,Ltd.
23-06-20
CI
HLB Therapeutics Co.,Ltd. announced that it has received KRW 2.5 billion in funding
23-06-15
CI
HLB Therapeutics Co.,Ltd. announced that it has received KRW 5 billion in funding
23-06-15
CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors
23-03-12
CI
Oblato, Inc. announced that it has received KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd.
23-02-13
CI
Oblato, Inc. announced that it expects to receive KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd.
23-02-05
CI
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors
23-01-31
CI
HLB Therapeutics Co.,Ltd. announced that it has received KRW 13.0088 billion in funding from HLB Co., Ltd.
23-01-11
CI
HLB Therapeutics to Raise 13 Billion Won via Stock Sale
23-01-04
MT
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 13.0088 billion in funding from HLB Co., Ltd.
23-01-03
CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-14
CI
HLB Therapeutics Submits Phase 3 Protocol for Neurotrophic Keratopathy
22-09-27
CI
HLB Therapeutics Signs Letter of Intent with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis
22-07-18
CI
G-treeBNT Co., Ltd. announced that it has received KRW 95.000054256 billion in funding from a group of investors
21-11-15
CI
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 95.000054256 billion in funding from a group of investors
21-09-12
CI
G-treeBNT Co., Ltd. announced that it has received KRW 10 billion in funding from Shinhan Investment Corp., BFA Co.,Ltd., Bayside Private Equity
21-07-27
CI
G-Tree Holdings Co.,Ltd. completed the acquisition of 2.65% stake in G-treeBNT Co., Ltd. from Yang Won-seok for KRW 16.9 billion.
21-02-25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
HLB Therapeutics Co Ltd, formerly G-treeBNT Co Ltd, is a Korea-based company engaged in the research and development of optimized multimedia software for various digital appliances including cellular phones. Along with its affiliates, the Company operates solution business segment, which provides embedded graphic user interface (GUI) software solutions as well as wired and wireless integration multimedia platform solutions. Its embedded GUI products include FXUI-two-dimensional (2D), FXUI-three-dimensional (3D) and FX Studio, which are used for cellular phones and embedded equipment. Its wired and wireless integration multimedia platform products include FX-Flash and others, which are used for cellular phones and other mobile devices; electronic components manufacturing business segment, which provides transformers, pumps, motors and others, as well as educational and bio pharmaceutical business segments.
More about the company
1st Jan change
Capi.
+113.00% 538M +20.94% 72.78B -1.26% 24.24B +8.80% 8.59B +8.25% 8.38B -19.42% 8.09B +5.62% 4.81B +16.83% 4.32B -1.83% 4.05B +26.97% 3.79B
Pharmaceuticals Wholesale
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1